Healthcare
Live Price
Offline$42.38
-0.28% today
1Y Change
-10.83%
Window
Jun 23, 2025 → Jun 1, 2026
Coverage: 236 bars · Jun 23, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sanofi (SNY) is a Healthcare stock with a market cap of $96.03B and listed on NASDAQ. The stock last traded around $42.38 and down 10.8% across the available one-year price window (Jun 23, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +5.5%, EPS growth of -7.7%, a dividend yield of 4.9%. What stands out right now is revenue +5.5%, EPS -7.7%, free cash flow +51.1% with operating margin 25.1% and ROIC 11.7%. The dividend matters to the case here, with a current yield around 4.9%. Valuation is more restrained than many high-expectation growth names at P/E 9.3 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNY Max Drawdown
-18.95%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$39.2B
-3.4% YoY
FY Net Income
$6.2B
-25.7% YoY
Free Cash Flow
$8.5B
+1.8% YoY
Revenue Growth
+5.5%
EPS Growth
-7.7%
Gross Margin
71.6%
Net Margin
17.6%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 46.7B | 44.3B | 41.6B | 40.6B | 39.2B |
| Gross Profit | 33.8B | 31.1B | 29.0B | 28.7B | 26.9B |
| Operating Income | 6.3B | 7.3B | 7.0B | 10.2B | 8.1B |
| EBITDA | 12.7B | 11.0B | 11.4B | 13.5B | 11.5B |
| Net Income | 7.8B | 5.6B | 5.4B | 8.4B | 6.2B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.7B | 7.4B | 8.7B | 12.7B | 10.1B |
| Total Assets | 126.8B | 132.8B | 126.5B | 126.7B | 120.2B |
| Total Liabilities | 55.1B | 54.9B | 52.1B | 51.6B | 51.2B |
| Shareholder Equity | 71.4B | 77.5B | 74.0B | 74.8B | 68.7B |
| Total Debt | 21.8B | 17.9B | 18.7B | 21.2B | 22.4B |
| Net Debt | 14.1B | 10.5B | 10.0B | 8.5B | 12.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10.5B
-0.0% YoY
Capital Expenditures
2.0B
+7.2% YoY
Free Cash Flow
8.5B
+1.8% YoY
Key ratios
Gross Margin
71.6%
Operating Margin
25.1%
Net Margin
17.6%
ROE
14.4%
Debt / Equity
0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.